Treating hepatitis C: Current standard of care and emerging direct-acting antiviral agents

Journal of Viral Hepatitis

Volumn 19, Issue 7, 2012, Pages 449-464

  Poordad, F ^a   Dieterich, D ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antiviral agents; Hepatitis C; Treatment

Indexed keywords

ABT 072; ACH 1625; ACH 2684; ACH 2928; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; INX 189; MERICITABINE; MK 5172; N (2' DEOXY 2' FLUORO 2' METHYL P PHENYL 5' URIDYLYL)ALANINE ISOPROPYL ESTER; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SETROBUVIR; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; VCH 222; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

5' UNTRANSLATED REGION; ANEMIA; ANTIVIRAL ACTIVITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IC 50; INTERNAL RIBOSOME ENTRY SITE; JAUNDICE; MOLECULAR BIOLOGY; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84862161013     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01617.x     Document Type: Review

References (89)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144(10): 705-714. (Pubitemid 46780630)
2. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31(Suppl 1): 80-83. (Pubitemid 30002696)
3. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29(Suppl 1): 1-8.
4. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74-81.
5. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011; 171(3): 242-248.
6. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(3 Suppl. 1): 62S-65S. (Pubitemid 27388074)
7. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8(11): 924-933.
8. Gonzalez SA. Management of recurrent hepatitis C following liver transplantation. Gastroenterol Hepatol 2010; 6(10): 637-645.
9. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47(4): 1128-1135. (Pubitemid 351547899)
10. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24(4): 778-789. (Pubitemid 26334273)
11. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
12. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965. (Pubitemid 32913521)
13. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361(6): 580-593.
14. Andre P, Perlemuter G, Budkowska A, Brechot C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 2005; 25(1): 93-104. (Pubitemid 40322354)
15. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278(42): 41003-41012. (Pubitemid 37280923)
16. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 1998; 282(5390): 938-941. (Pubitemid 28507525)
17. Bartosch B, Verney G, Dreux M et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79(13): 8217-8229. (Pubitemid 40853525)
18. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446(7137): 801-805. (Pubitemid 46582027)
19. Blanchard E, Belouzard S, Goueslain L et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80(14): 6964-6972. (Pubitemid 44025195)
20. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008; 10(4): 821-827. (Pubitemid 351386938)
21. Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol 2011; 7(3): 154-162.
22. O'Leary JG, Davis GL. Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol 2010; 3(1): 43-53.
23. Uprichard SL. Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin 2010; 25(4): 227-245.
24. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132(5): 1979-1998. (Pubitemid 46695724)
25. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5(6): 453-463. (Pubitemid 46780082)
26. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282(5386): 103-107. (Pubitemid 28471138)
27. Glenn JS. Molecular virology of the hepatitis C virus: implication for novel therapies. Clin Liver Dis 2005; 9(3): 353-369. v. (Pubitemid 40968200)
28. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285(5424): 110-113. (Pubitemid 29307577)
29. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11(7): 791-796. (Pubitemid 41021213)
30. Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med 2010; 2: 125-145.
31. Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007; 13(17): 2406-2415. (Pubitemid 46929495)
32. Sakai A, Claire MS, Faulk K et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Nat Acad Sci USA 2003; 100(20): 11646-11651. (Pubitemid 37205990)
33. Kronenberger B, Welsch C, Forestier N, Zeuzem S. Novel hepatitis C drugs in current trials. Clin Liver Dis 2008; 12(3): 529-555. viii. (Pubitemid 351958486)
34. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3(3): 191-202.
35. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4(3): e1000032.
36. McCown MF, Rajyaguru S, Le Pogam S et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52(5): 1604-1612. (Pubitemid 351614649)
37. Watashi K, Ishii N, Hijikata M et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19(1): 111-122. (Pubitemid 40884662)
38. Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131(4): 997-1002. (Pubitemid 44498690)
39. Forestier N, Reesink HW, Weegink CJ et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46(3): 640-648. (Pubitemid 47436108)
40. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46(3): 631-639. (Pubitemid 47436107)
41. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405-2416.
42. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364(25): 2417-2428.
43. Vertex Pharmaceuticals Inc. Incivek [package insert]. 2011. Available at: http://pi.vrtx.com/files/uspi-telaprevir.pdf (accessed 12 December 2011).
44. Vertex Pharmaceuticals Inc. Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment [Press Release]. 2011. Avaliable at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=525062 (accessed 22 August 2011).
45. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195-1206.
46. Merck & Co. Victrelis [Package Insert]. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf (accessed 22 August 2011).
47. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207-1217.
48. Zeuzem S, Foster GR, Fried MW, et al. The ASPIRE trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: week 24 interim analysis. European Association for the Study of the Liver 46th Annual Meeting. Berlin, Germany, 2011.
49. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366(3): 216-224.
50. Sulkowski M, Ceasu E, Asselah T et al. Sustained virologic response (SVR) and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1HCV. J Hepatol 2011; 54(Suppl 1): S27.
51. Sulkowski M, Bourliere M, Bronowicki J et al. SILEN-C2: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R. J Hepatol 2011; 54(Suppl 1): S30.
52. Sane R, Podila L, Mathur A et al. Mechanisms of isolated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54(Suppl 1): S488.
53. Stauber K, Kapoor P, Marlor C, Mushtaq G, et al. Characterization of the hepatoselective distribution of ACH-1625: a potent, clinical stage HCV NS3 protease inhibitor. 45th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, 2010. Abstract 172.
54. Detishin V, Haazen W, Robison H, Robarge L, Olek E. Virological response, safety, and pharmacokinetic profile following single-and multiple-dose administration of ACH-1625 protease inhibitor to healthy volunteers and HCV genotype-1 patients. 45th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, 2010. Abstract 2012.
55. Huang M, Agarwal A, Stauber K, et al. ACH-1625 demonstrates sustained viral suppression in presence of uncommon drug resistant HCV. Liver Meeting. Boston, MA, 2010.
56. Agarwal A. Viral kinetics modeling of short-term monotherapy data of ACH-1625. Asian Pacific Association for the Study of the Liver.Bangkok, 2010.
57. Achillion Pharmaceuticals Inc. Achillion Reports Clinical Data on Portfolio of Protease Inhibitors. 2012. Available at: http://ir.achillion.com/ releasedetail.cfm?ReleaseID=637751 (accessed 23 January 2012).
58. Forestier N, Larrey D, Guyader D et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 2011; 54: 1130-1136.
59. Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376(9751): 1467-1475.
60. Liverton NJ, Carroll SS, Dimuzio J et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010; 54(1): 305-311.
61. Manns M, Gane E, Rodriguez-Torres M, et al. MK-7009 significantly improves Rapid Viral Response (RVR) in combination with pegylated Interferon Alfa-2a and ribavirinin patients with Chronic Hepatitis C (CHC) genotype 1 infection. EASL 44th Annual Meeting. Copenhagen, 2009.
62. Petry A, Brainard D, Van Dyck K, et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. 61st Annual Meeting of the American Association for the Study of Liver Disease. Boston, MA, 2010.
63. Huang M, Podos S, Patel D et al. ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. Hepatology 2010; 52(Suppl. 4): 1204A.
64. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465(7294): 96-100.
65. Huang M, Yang G, Patel D, et al. ACH-2928: a Novel highly potent HCV NS5A inhibitor with favorable preclinical characteristics. European Association for the Study of the Liver. Berlin, 2011.
66. Pockros P, Jensen D, Tsai N, et al. IRST SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. European Association for the Study of the Liver. Berlin, 2011.
67. Clinical Trials.gov. PSI-7977 with pegylated interferon and ribavirin Hepatitis C Virus (HCV) genotypes 1,4,5,6 (ATOMIC). 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01329978?term=PSI-7977&rank=2 (accessed 22 August 2011).
68. Nelson D, Lalezari J, Lawitz E, et al. Once daily PSI-7977 plus Peg-IFN/RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: the PROTON study [poster]. European Association for the Study of the Liver. Berlin, 2011.
69. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PegIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. European Association for the Study of the Liver. Berlin, Germany, 2011. Abstract 325.
70. Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon-ALFA not required for complete rapid viral response in treatment-naïve patients with HCV GT2 or GT3. The Liver Meeting 2011: American Association for the Study of Liver Diseases (AASLD) 62nd Annual Meeting. Boston, MA, 2011.
71. Pharmasset Inc. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV. 2011. Available at: http://investor. pharmasset.com/releasedetail.cfm?ReleaseID=619564 (accessed 23 January 2012).
72. Hall A, Raja N, Chamberlain SD et al. Metabolite characterization of INX-189, a potent HCV inhibitor, in fresh human primary hepatocytes and human liver and kidney cell lines. Hepatology 2010; 52(Suppl. 4): 1211A.
73. Vernachio J, Bryant D, Chamberlain SD et al. In vitro and in vivo metabolism of INX-189, a potent HCV inhibitor, in rat and cynomolgus monkey hepatocytes. Hepatology 2010; 52(Suppl. 4): 1218A.
74. Kolykhalov A, Liu Y, Bleiman B, Patti J, McGuigan C, Vernachio J. Characterization of in vitro selected hepatitis C virus replicon mutants resistant to the phosphoramidate analog of 2′-C-methylguanosine, INX-189. Hepatology 2010; 52(Suppl. 4): 1218A.
75. Conference Reports for NATAP. Inhibitex reports positive safety and antiviral data from its phase 1b study of HCV nucleotide inhibitor INX-189. Available at: http://www.natap.org/2011/EASL/EASL-90.htm. 2011 (accessed on 12 December 2011).
76. Wagner F, Thompson R, Kantaridis C et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1 infected patients. Hepatology 2011; 54: 50-59.
77. Clinical Trials.gov. Changes to NCT00875628. ClinicalTrials.gov archive. 2011. Available at: http://clinicaltrials.gov/archive/NCT00875628/2009-10-21/ changes (accessed 12 December 2011).
78. Bedard J, Nicolas O, Bilimoria D, et al. Identification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor [Abstract 935]. 44th Annual Meeting of the European Association for the Study of the Liver. Copenhagen, 2009.
79. Gaultier I, Cohen D, Dumas E, et al. 12-week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-Naive subjects. 21st Conference of the Asian Pacific Association for the Study of the Liver. Bangkok, 2011.
80. Clinical Trials.gov. Safety and efficacy of ANA598 administered with pegylated interferon and ribavirin in genotype-1 patients with chronic HCV infection. 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01281423? term=ANA-598&rank=3, 2011 (accessed 12 December 2011).
81. Coelmont L, Hanoulle X, Chatterji U et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cistrans isomerisation in domain II of NS5A. PLoS One 2010; 5(10): e13687.
82. Flisiak R, Feinman SV, Jablkowski M et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49(5): 1460-1468.
83. Flisiak R, Pawlotsky JM, Crabbe R et al. Once daily alisporivir (DEB025) plus pegIFN alfa-2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients. European Association for the Study of the Liver, Berlin 2011.
84. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepatitis 2009; 16(6): 377-387.
85. Forestier N, Susser S, Welker M et al. Long-term followup of patients previously treated with telaprevir [abstract 1011]. Hepatology 2008; 48: 760A.
86. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106(1): 38-45.
87. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.
88. Hitomi Y, Cirulli ET, Fellay J et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011; 140(4): 1314-1321.
89. Thompson AJ, Santoro R, Piazzolla V et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011; 53: 389-395.